MSD Partners’s MedTech Acquisition Corporation Unit MTACU Stock Holding History

MSD Partners’s Portfolio MTACU Stock Details MTACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,200,000	Closed	-$12M	–	124
2021 Q4	$12M	Buy	1,200,000 +800,000	+200%	+$8.19M	0.13%	47
2021 Q3	$4.06M	Hold	400,000	–	–	0.12%	43
2021 Q2	$4.01M	Hold	400,000	–	–	0.1%	50
2021 Q1	$4.02M	Hold	400,000	–	–	0.15%	44
2020 Q4	$4.2M	Buy	+400,000	New	+$4.17M	0.7%	22

Other funds holding MTACU

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

ICMH

Integrity Capital Management (HK) Central, Hong Kong $64K AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

MSD Partners's MTACU Position: Q1 2022 in Review

MSD Partners sold out of MedTech Acquisition Corporation Unit (MTACU) in Q1 2022, closing a stake of 1,200,000 shares — an estimated $12M sold.

MSD Partners first reported a position in MTACU in Q4 2020 and held it in 5 quarters. The position peaked at $12M in Q4 2021. 5 funds tracked by Wall St. Rank hold MTACU as of Q1 2022.

MSD Partners reported no remaining MedTech Acquisition Corporation Unit position as of Q1 2022 after selling out during the quarter.
MSD Partners sold 1,200,000 MedTech Acquisition Corporation Unit shares in Q1 2022, an estimated $12M.
MSD Partners first reported a position in MedTech Acquisition Corporation Unit in Q4 2020 and held it in 5 quarters.
MSD Partners's MedTech Acquisition Corporation Unit position peaked at $12M in Q4 2021.
5 funds tracked by Wall St. Rank held MedTech Acquisition Corporation Unit as of Q1 2022.

Based on MSD Partners's 13F filing for Q1 2022, filed 16 May 2022.